Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-630P, or RNA, U6 small nuclear 630, pseudogene, is a human genome locus classified as a pseudogene derived from the U6 small nuclear RNA gene family[2]. The parent molecule, U6 snRNA, is an integral component of the spliceosome complex, playing an essential role in precursor mRNA splicing by facilitating intron excision within the nucleus[3][5]. U6 snRNA itself is highly conserved and crucial to the splicing process, but pseudogenes like RNU6-630P result from retrotransposition events or genomic duplications and do not produce functional RNA[7][1]. While these pseudogenes are no longer functional, their presence in the genome can reflect the activity of retrotransposition mechanisms—especially those mediated by LINE-1 elements—or act as evolutionary markers. RNU6-630P is not a protein, receptor, enzyme, or factor involved in cell signaling, and it does not have therapeutic relevance as a direct drug target[2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 630, pseudogene (RNU6-630P).